Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain
Completed
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase 1/Phase 2
2004-12-01
This study will test a combination of the drugs naltrexone and bupropion with
weight-concerned smokers to investigate whether or not this combination of drugs improves
smoking cessation quit rates and minimizes post quit weight gain.
Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain
Completed
Yale University
Phase 1/Phase 2
2004-12-01
This study will test a combination of the drugs naltrexone and bupropion with
weight-concerned smokers to investigate whether or not this combination of drugs improves
smoking cessation quit rates and minimizes post quit weight gain.
Abilify Therapy for Reducing Comorbid Substance Abuse
Completed
Bristol-Myers Squibb
Phase 4
2005-03-01
It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or
drug dependence with comorbid psychiatric conditions will lead to:
- Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow
Back (TLFB) and the Addiction Severity Index (ASI)
- Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving
Scale
- Reduction in symptoms of co-morbid psychiatric disorders compared to before starting
aripiprazole.
Abilify Therapy for Reducing Comorbid Substance Abuse
Completed
Creighton University
Phase 4
2005-03-01
It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or
drug dependence with comorbid psychiatric conditions will lead to:
- Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow
Back (TLFB) and the Addiction Severity Index (ASI)
- Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving
Scale
- Reduction in symptoms of co-morbid psychiatric disorders compared to before starting
aripiprazole.
Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity
Completed
Orexigen Therapeutics, Inc
Phase 2
2005-04-01
The purpose of this study is to determine the efficacy and safety of 3 combinations of
naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
